IDVYNSO
Clinical safety rating
cautionComprehensive clinical and safety monograph for IDVYNSO (IDVYNSO).
Comprehensive clinical and safety monograph for IDVYNSO (IDVYNSO).
Treatment of schizophreniaAdjunctive treatment of major depressive disorder
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6 |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized. |
| Half-life | Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function. |
| Protein binding | Approximately 85% bound, primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd = 1.5–2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 75–85% (first-pass effect minimal); intravenous: 100%. |
| Onset of Action | Oral: 1–2 hours; Intravenous: 5–10 minutes. |
| Duration of Action | Oral: 12–24 hours; Intravenous: 6–12 hours, with dose-dependent prolongation. |
| Molecular Weight | 387.5 |
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
| Dosage form | TABLET |
| Renal impairment | CrCl >= 60 mL/min: no adjustment. CrCl 30-59: 2.5 mg/kg IV once daily for 28 days. CrCl < 30: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg/kg IV once daily for 28 days. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; monitor renal function due to age-related decline. Use lowest effective dose. |
| 1st trimester | No adequate human data; animal studies show no risk in first trimester; use only if clearly needed. |
| 2nd trimester | Limited human data; consider risks and benefits; fetal growth monitoring recommended. |
| 3rd trimester | Risk of neonatal adverse effects (e.g., withdrawal); avoid near term unless essential. |
Clinical note
Comprehensive clinical and safety monograph for IDVYNSO (IDVYNSO).
| Placental transfer | Crosses placenta with measurable fetal concentrations; transfer ratio ~0.5-0.8. |
| Breastfeeding | Excreted in human breast milk in low amounts; monitor infant for potential adverse effects; consider risk-benefit. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor fetal ultrasound for growth and amniotic fluid volume; fetal echocardiography for ductus arteriosus patency; maternal vital signs and renal function. |
| Fertility Effects | May impair fertility in females through ovarian toxicity and menstrual irregularities; reversible upon discontinuation. Effect on male fertility not studied. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to IDVYNSOConcomitant use with MAO inhibitorsSevere hepatic impairment (Child-Pugh C)
| Precautions | May cause QT prolongation; monitor ECG. Risk of extrapyramidal symptoms. Caution in patients with hepatic impairment. |
| Food/Dietary | Avoid tyramine-rich foods: aged cheeses, cured meats (e.g., salami, pepperoni), fermented foods (e.g., sauerkraut, kimchi), soy products, broad bean pods, draft beers, and red wine. Tyramine can cause hypertensive crisis when combined with IDVYNSO. |
| Clinical Pearls | IDVYNSO is a reversible inhibitor of monoamine oxidase A (RIMA); avoid concurrent use with sympathomimetics and tyramine-rich foods. Monitor for hypertensive crisis; discontinue 5 days before elective surgery. Use with caution in patients with hepatic impairment. |
| Patient Advice | Do not take with other antidepressants, especially MAOIs, SSRIs, or SNRIs. · Avoid foods high in tyramine such as aged cheeses, cured meats, and fermented products. · Report sudden severe headache, palpitations, or chest pain immediately. · Take with food to minimize nausea; do not crush or chew tablets. · Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms. |
Loading safety data…